Stockscreener 앱 받기
45.94
1.29%
-0.6367
전일 마감가:
$46.58
열려 있는:
$46.86
하루 거래량:
95,630
Relative Volume:
0.14
시가총액:
$1.78B
수익:
$17.39M
순이익/손실:
$-135.89M
주가수익비율:
-13.59
EPS:
-3.38
순현금흐름:
$-123.00M
1주 성능:
-1.44%
1개월 성능:
+26.15%
6개월 성능:
+21.54%
1년 성능:
+161.70%
1일 변동 폭
$45.19
$47.36
1주일 범위
$43.25
$47.37
52주 변동 폭
$15.60
$52.99
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
TARS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TARS | 45.98 | 1.78B | 17.39M | -135.89M | -123.00M | -3.38 |
| VRTX | 448.10 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.65 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.86 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade - Yahoo Finance
22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP - MarketBeat
What is Lifesci Capital's Forecast for TARS FY2024 Earnings? - MarketBeat
Tarsus Pharmaceuticals Appoints Kate Goodrich, MD, to its Board of Directors - Vision Monday
US$65.33That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results - Simply Wall St
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.3%Here's What Happened - MarketBeat
Midday Stock Roundup: Viant Tech Up Since Q3 Earnings - Orange County Business Journal
Trend Tracker for (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales By Investing.com - Investing.com UK
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharma - GuruFocus.com
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharm - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year High After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $52 - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $52 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance - TipRanks
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings: EPS of $(0.6 - GuruFocus.com
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements - GlobeNewswire
Tarsus Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors - The Manila Times
Tarsus Pharma Strengthens Board with Humana CMO Dr. Kate Goodrich Appointment | TARS Stock News - StockTitan
Jennison Associates LLC Increases Stake in Tarsus Pharmaceuticals Inc - GuruFocus.com
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer - Vision Monday
Lisanti Capital Growth LLC Takes $1.31 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled - MSN
Creative Planning Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesday - MarketBeat
Creative Planning Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - GlobeNewswire
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 - Investing.com
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals Inc (TARS-Q) QuotePress Release - The Globe and Mail
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - GlobeNewswire
Tarsus Pharmaceuticals appoints new Chief Medical Officer - Investing.com India
Tarsus Pharmaceuticals appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Papulopustular Rosacea Market to Expand Significantly by 2034, States DelveInsight Report | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart
Papulopustular Rosacea Market to Expand Significantly by 2034, - openPR
Tarsus Pharma Names Leading Ophthalmologist Dr. Elizabeth Yeu as New Chief Medical Officer | TARS Stock News - StockTitan
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Tarsus Pharmaceuti - GuruFocus.com
Emerald Advisers LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):